What is claimed is:

1. An isolated antibody or antigen-binding fragment thereof that specifically binds ErbB3 and blocks NRG1 binding to ErbB3 with an IC_{50} of less than 30 pM in an ELISA at 25°C.

2. An isolated antibody or antigen-binding fragment thereof that specifically binds ErbB3 and inhibits at least 65% of NRG1-induced phosphorylation of Akt in tumor cells *in vitro*.

3. An isolated antibody or antigen-binding fragment thereof that specifically binds ErbB3 and reduces NRG1-induced tumor cell growth *in vitro* by at least 60% when combined with an inhibitor of EGFR or ErbB2.

4. The isolated antibody or antigen-binding fragment of any one of claims 1 to 3, wherein the antibody or antigen-binding fragment binds an epitope within Domain III of the extracellular domain of ErbB3 (amino acids 309 to 499 of SEQ ID NO:498).

5. The antibody or antigen-binding fragment of claim 4, wherein the antibody or antigen-binding fragment interacts with one or more amino acids located within one or more amino acid segments selected from the group consisting of amino acids 345-367 of SEQ ID NO:498, amino acids 423-439 of SEQ ID NO:498, and amino acids 451-463 of SEQ ID NO:498.

6. The antibody or antigen-binding fragment of claim 5, wherein the antibody or antigen-binding fragment interacts with amino acids 345-367 of SEQ ID NO:498, amino acids 423-439 of SEQ ID NO:498; and amino acids 451-463 of SEQ ID NO:498, as determined by hydrogen/deuterium exchange.

7. An isolated antibody or antigen-binding fragment thereof that specifically binds ErbB3, wherein the antibody or antigen-binding fragment competes for binding to ErbB3 with a reference antibody comprising an HCVR/LCVR sequence pair having SEQ ID NOs: 306/314 or 322/330.

8. An isolated antibody or antigen-binding fragment thereof that specifically binds ErbB3, wherein the antibody or antigen-binding fragment binds to the same epitope on ErbB3 as a reference antibody comprising an HCVR/LCVR sequence pair having SEQ ID NOs: 306/314 or 322/330.

9. An isolated antibody, or antigen-binding fragment thereof, that specifically binds ErbB3, wherein the antibody or antigen-binding fragment comprises: (a) the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322, 338, 354, 370, 386, 402, 418,

434, 450, 466 and 482; and (b) the CDRs of a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362, 378, 394, 410, 426, 442, 458, 474 and 490.

10. The isolated antibody or antigen-binding fragment of claim 9, wherein the antibody or antigen-binding fragment comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 370/378, 386/394, 402/410, 418/426, 434/442, 450/458, 466/474 and 482/490.

11. The isolated antibody or antigen-binding fragment of claim 10, wherein the antibody or antigen-binding fragment comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, respectively, selected from the group consisting of: SEQ ID NOs: 4-6-8-12-14-16; 20-22-24-28-30-32; 36-38-40-44-46-48; 52-54-56-60-62-64; 68-70-72-76-78-80; 84-86-88-92-94-96; 100-102-104-108-110-112; 116-118-120-124-126-128; 132-134-136-140-142-144; 148-150-152-156-158-160; 164-166-168-172-174-176; 180-182-184-188-190-192; 196-198-200-204-206-208; 212-214-216-220-222-224; 228-230-232-236-238-240; 244-246-248-252-254-256; 260-262-264-268-270-272; 276-278-280-284-286-288; 292-294-296-300-302-304; 308-310-312-316-318-320; 324-326-328-332-334-336; 340-342-344-348-350-352; 356-358-360-364-366-368; 372-374-376-380-382-384; 388-390-392-396-398-400; 404-406-408-412-414-416; 420-422-424-428-430-432; 436-438-440-444-446-448; 452-454-456-460-462-464; 468-470-472-476-478-480; and 484-486-488-492-494-496.

12. An isolated antibody, or antigen-binding fragment thereof, that specifically binds ErbB3, wherein the antibody or antigen-binding fragment comprises: (a) a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322, 338, 354, 370, 386, 402, 418, 434, 450, 466 and 482; and (b) a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362, 378, 394, 410, 426, 442, 458, 474 and 490.

13. The isolated antibody or antigen-binding fragment of claim 12, wherein the antibody or antigen-binding fragment comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 370/378, 386/394, 402/410,

418/426, 434/442, 450/458, 466/474 and 482/490.

14. A pharmaceutical composition comprising the antibody or antigen-binding fragment of any one of claims 1 to 3 or 7 to 13, and a pharmaceutically acceptable carrier or diluent.

15. A method for inhibiting tumor growth, the method comprising administering the pharmaceutical composition of claim 14 to a subject afflicted with a tumor.

16. The method of claim 15, wherein the tumor is selected from the group consisting of a renal tumor, a pancreatic tumor, a breast tumor, a prostate tumor, a colon tumor, a gastric tumor, and ovarian tumor, a lung tumor, and a skin tumor.

17. A method for inhibiting or attenuating tumor growth in a subject, the method comprising administering to the subject an antibody that specifically binds ErbB3 or an antigen-binding fragment thereof, and a second therapeutic agent, wherein the second therapeutic agent is an antibody or antigen-binding fragment thereof that specifically binds EGFR or HER2.

18. The method of claim 17, wherein the antibody that specifically binds ErbB3 is an antibody or antigen-binding fragment that comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 370/378, 386/394, 402/410, 418/426, 434/442, 450/458, 466/474 and 482/490.

19. The method of claim 17, wherein the second therapeutic agent is an antibody or antigen-binding fragment thereof that specifically binds EGFR.

20. The method of claim 17, wherein the second therapeutic agent is an antibody or antigen-binding fragment thereof that specifically binds HER2.

21. The method of claim 17, wherein the antibody that specifically binds ErbB3 comprises an HCVR/LCVR sequence pair having SEQ ID NO: 306/314 or 322/330.

22. The pharmaceutical composition of claim 14 for use in inhibiting tumor growth in a subject afflicted with a tumor.

23. The pharmaceutical composition of claim 22, wherein the subject is afflicted with a tumor selected from the group consisting of a renal tumor, a pancreatic tumor, a breast tumor, a prostate tumor, a colon tumor, a gastric tumor, and ovarian tumor, a lung tumor, and a skin tumor.

24. An antibody that specifically binds ErbB3 or an antigen-binding fragment thereof for

use in inhibiting or attenuating tumor growth in a subject, wherein the antibody or antigen-binding fragment thereof is administered in combination with a second therapeutic agent, wherein the second therapeutic agent is an antibody or antigen-binding fragment thereof that specifically binds EGFR or HER2.

25. The antibody or antigen-binding fragment of claim 24, wherein the antibody or antigen-binding fragment comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 370/378, 386/394, 402/410, 418/426, 434/442, 450/458, 466/474 and 482/490.

26. The antibody or antigen-binding fragment of claim 24, wherein the second therapeutic agent is an antibody or antigen-binding fragment thereof that specifically binds EGFR.

27. The antibody or antigen-binding fragment of claim 24, wherein the second therapeutic agent is an antibody or antigen-binding fragment thereof that specifically binds HER2.

28. The antibody or antigen-binding fragment of claim 24, wherein the antibody or antigen-binding fragment comprises an HCVR/LCVR sequence pair having SEQ ID NO: 306/314 or 322/330.

What is claimed is:

1. An isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds ErbB3, wherein the antibody or antigen-binding fragment interacts with amino acids 345-367 of SEQ ID NO:498, amino acids 423-439 of SEQ ID NO:498; and amino acids 451-463 of SEQ ID NO:498, as determined by hydrogen/deuterium exchange.

2. An isolated monoclonal antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 domains, respectively, selected from the group consisting of: SEQ ID NOs: 308, 310, 312, 316, 318 and 320; and 324, 326, 328, 332, 334 and 336.

3. An isolated monoclonal antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 306/314, and 322/330.

4. A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 2 and a pharmaceutically acceptable carrier or diluent.

5. A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 1 and a pharmaceutically acceptable carrier or diluent.

6. A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 3 and a pharmaceutically acceptable carrier or diluent.

7. The isolated antibody or antigen-binding fragment of claim 2, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 domains having the amino acid sequence, respectively, of SEQ ID NOs: 324, 326, 328, 332, 334 and 336.

8. The isolated antibody or antigen-binding fragment of claim 3, wherein the antibody or antigen-binding fragment comprises a HCVR having the amino acid sequence of SEQ ID NO:322 and a LCVR having the amino acid sequence of SEQ ID NO:330.